Upcoming Dividend • May 13
Upcoming dividend of €0.12 per share Eligible shareholders must have bought the stock before 20 May 2026. Payment date: 22 May 2026. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.7%). Major Estimate Revision • Apr 16
Consensus EPS estimates fall by 63% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €38.6m to €37.3m. Losses expected to increase from €0.27 per share to €0.44. Chemicals industry in Germany expected to see average net income growth of 44% next year. Consensus price target of €25.00 unchanged from last update. Share price rose 17% to €15.95 over the past week. Major Estimate Revision • Mar 20
Consensus EPS estimates fall by 21% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €45.0m to €44.3m. Losses expected to increase from €0.14 per share to €0.17. Chemicals industry in Germany expected to see average net income growth of 55% next year. Consensus price target of €25.00 unchanged from last update. Share price fell 6.7% to €17.35 over the past week. New Risk • Mar 19
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €2.8m Forecast net loss in 2 years: €209k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€209k net loss in 2 years). Share price has been volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$100m (€86.5m market cap, or US$99.5m). New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). New Risk • Feb 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €82.4m (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$100m (€82.4m market cap, or US$97.9m). New Risk • Dec 31
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €2.8m Forecast net loss in 2 years: €1.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (26% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Major Estimate Revision • Nov 15
Consensus EPS estimates fall by 38% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.50 to -€0.69 per share. Revenue forecast of €45.0m unchanged since last update. Chemicals industry in Germany expected to see average net income growth of 20% next year. Consensus price target of €14.30 unchanged from last update. Share price was steady at €18.30 over the past week. Price Target Changed • Nov 04
Price target increased by 93% to €14.30 Up from €7.40, the current price target is an average from 2 analysts. New target price is 26% below last closing price of €19.30. Stock is up 93% over the past year. The company is forecast to post a net loss per share of €0.50 next year compared to a net loss per share of €1.12 last year. New Risk • Oct 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 23% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risk Market cap is less than US$100m (€80.8m market cap, or US$94.6m). New Risk • Jul 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (€32.8m market cap, or US$38.3m). Announcement • Jun 24
IBU-tec advanced materials AG to Report First Half, 2025 Results on Aug 27, 2025 IBU-tec advanced materials AG announced that they will report first half, 2025 results on Aug 27, 2025 Major Estimate Revision • May 23
Consensus revenue estimates decrease by 18%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €55.1m to €45.3m. EPS estimate increased from -€1.02 to -€0.69 per share. Chemicals industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €7.40 to €7.60. Share price rose 8.6% to €7.10 over the past week. Reported Earnings • May 19
Full year 2024 earnings: Revenues in line with analyst expectations Full year 2024 results: Revenue: €54.1m (up 10% from FY 2023). Net loss: €5.31m (loss widened 113% from FY 2023). Revenue was in line with analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Chemicals industry in Germany. New Risk • May 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€31.1m market cap, or US$34.6m). Announcement • Apr 17
IBU-tec advanced materials AG, Annual General Meeting, May 26, 2025 IBU-tec advanced materials AG, Annual General Meeting, May 26, 2025, at 10:00 W. Europe Standard Time. Announcement • Apr 16
Ibu-Tec Advanced Materials Ag Provides Revenue Guidance for 2025 Ibu-Tec Advanced Materials Ag provided Revenue Guidance for 2025. For the period, the company expected revenue EUR 43 million to EUR 45 million after consolidated revenues of around EUR 50.6 million in the past financial year according to preliminary unaudited figures. New Risk • Mar 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€28.3m market cap, or US$30.8m). Announcement • Jan 08
IBU-tec advanced materials AG to Report Fiscal Year 2024 Results on Mar 20, 2025 IBU-tec advanced materials AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Mar 20, 2025 Major Estimate Revision • Dec 04
Consensus EPS estimates fall by 116% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from €54.3m to €50.9m. Losses expected to increase from €0.62 per share to €1.34. Chemicals industry in Germany expected to see average net income growth of 37% next year. Consensus price target down from €12.00 to €7.40. Share price rose 44% to €8.38 over the past week. New Risk • Dec 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (€36.1m market cap, or US$37.8m). Major Estimate Revision • Oct 13
Consensus EPS estimates fall by 107% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from €58.3m to €54.3m. Losses expected to increase from €0.30 per share to €0.62. Chemicals industry in Germany expected to see average net income growth of 59% next year. Consensus price target down from €14.50 to €12.00. Share price rose 16% to €10.90 over the past week. Reported Earnings • Sep 01
First half 2024 earnings released: €0.66 loss per share (vs €0.078 profit in 1H 2023) First half 2024 results: €0.66 loss per share (down from €0.078 profit in 1H 2023). Revenue: €25.3m (down 1.1% from 1H 2023). Net loss: €3.15m (down €3.53m from profit in 1H 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance. Announcement • Aug 29
IBU-tec advanced materials AG to Report First Half, 2024 Results on Aug 27, 2024 IBU-tec advanced materials AG announced that they will report first half, 2024 results on Aug 27, 2024 New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€34.8m market cap, or US$38.2m). Announcement • Mar 22
IBU-tec advanced materials AG, Annual General Meeting, Apr 30, 2024 IBU-tec advanced materials AG, Annual General Meeting, Apr 30, 2024. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to €12.72, the stock trades at a trailing P/E ratio of 51.8x. Average forward P/E is 18x in the Chemicals industry in Germany. Total loss to shareholders of 71% over the past three years. Announcement • Mar 21
IBU-tec advanced materials AG to Report Fiscal Year 2023 Results on Mar 21, 2024 IBU-tec advanced materials AG announced that they will report fiscal year 2023 results on Mar 21, 2024 New Risk • Mar 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€47.5m market cap, or US$51.9m). Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €17.14, the stock trades at a trailing P/E ratio of 69.8x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 54% over the past three years. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €13.96, the stock trades at a trailing P/E ratio of 56.9x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 42% over the past three years. Major Estimate Revision • Dec 24
Consensus revenue estimates fall by 23% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €60.0m to €46.3m. Forecast loss of -€0.62, down from profit of €0.01 per share profit previously. Chemicals industry in Germany expected to see average net income growth of 4.9% next year. Consensus price target down from €51.00 to €17.00. Share price fell 10% to €17.00 over the past week. New Risk • Dec 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €90.7m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk Market cap is less than US$100m (€90.7m market cap, or US$97.5m). New Risk • Oct 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (€84.6m market cap, or US$90.2m). New Risk • Oct 20
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.1m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Market cap is less than US$100m (€92.1m market cap, or US$97.5m). Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €19.38, the stock trades at a forward P/E ratio of 62x. Average forward P/E is 15x in the Chemicals industry in Germany. Total returns to shareholders of 51% over the past three years. Reported Earnings • Aug 30
First half 2023 earnings released: EPS: €0.078 (vs €0.10 in 1H 2022) First half 2023 results: EPS: €0.078 (down from €0.10 in 1H 2022). Revenue: €25.5m (down 14% from 1H 2022). Net income: €372.8k (down 24% from 1H 2022). Profit margin: 1.5% (down from 1.7% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Aug 28
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). Upcoming Dividend • Apr 20
Upcoming dividend of €0.04 per share at 0.1% yield Eligible shareholders must have bought the stock before 27 April 2023. Payment date: 02 May 2023. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.3%). Reported Earnings • Mar 27
Full year 2022 earnings released Full year 2022 results: Revenue: €56.0m (up 26% from FY 2021). Net income: €1.28m (up €1.52m from FY 2021). Profit margin: 2.3% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in Germany. Price Target Changed • Nov 16
Price target decreased to €58.00 Down from €64.50, the current price target is provided by 1 analyst. New target price is 118% above last closing price of €26.65. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.13 next year compared to a net loss per share of €0.049 last year. Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment improved over the past week After last week's 17% share price gain to €18.90, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 10x in the Chemicals industry in Germany. Total returns to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €17.60, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 9x in the Chemicals industry in Germany. Total returns to shareholders of 4.6% over the past three years. Reported Earnings • Sep 01
First half 2022 earnings released: EPS: €0 (vs €0.23 loss in 1H 2021) First half 2022 results: EPS: €0 (up from €0.23 loss in 1H 2021). Revenue: €30.7m (up 53% from 1H 2021). Net income: €491.3k (up €1.60m from 1H 2021). Profit margin: 1.6% (up from net loss in 1H 2021). Over the next year, revenue is forecast to grow 17%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Announcement • Aug 24
IBU-tec advanced materials AG to Report First Half, 2022 Results on Aug 31, 2022 IBU-tec advanced materials AG announced that they will report first half, 2022 results on Aug 31, 2022 Announcement • May 05
IBU-tec advanced materials AG, Annual General Meeting, May 04, 2022 IBU-tec advanced materials AG, Annual General Meeting, May 04, 2022. Reported Earnings • Apr 29
Full year 2021 earnings released Full year 2021 results: Revenue: €47.6m (up 45% from FY 2020). Net loss: €234.6k (down 123% from profit in FY 2020). Over the next year, revenue is forecast to grow 19%, compared to a 10% growth forecast for the industry in Germany. Price Target Changed • Apr 27
Price target increased to €64.50 Up from €38.73, the current price target is provided by 1 analyst. New target price is 90% above last closing price of €33.95. Stock is down 19% over the past year. The company is forecast to post earnings per share of €0.16 for next year compared to €0.25 last year. Reported Earnings • Mar 21
Full year 2020 earnings released The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €42.2m (down 14% from FY 2019). Net income: €1.00m (up 16% from FY 2019). Profit margin: 2.4% (up from 1.8% in FY 2019). The increase in margin was driven by lower expenses. Announcement • Mar 10
IBU-tec advanced materials AG has completed a Follow-on Equity Offering in the amount of €25.5 million. IBU-tec advanced materials AG has completed a Follow-on Equity Offering in the amount of €25.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 750,000
Price\Range: €34 Is New 90 Day High Low • Feb 01
New 90-day high: €39.00 The company is up 147% from its price of €15.80 on 03 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €122 per share. Price Target Changed • Jan 27
Price target raised to €33.50 Up from €18.10, the current price target is an average from 3 analysts. The new target price is 6.9% below the current share price of €36.00. As of last close, the stock is up 138% over the past year. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €27.40, the stock is trading at a trailing P/E ratio of 62.5x, down from the previous P/E ratio of 75.3x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 55%. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €30.80, the stock is trading at a trailing P/E ratio of 70.3x, down from the previous P/E ratio of 84x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 78%. Valuation Update With 7 Day Price Move • Dec 04
Market bids up stock over the past week After last week's 23% share price gain to €34.80, the stock is trading at a trailing P/E ratio of 79.4x, up from the previous P/E ratio of 64.4x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 112%. Valuation Update With 7 Day Price Move • Nov 19
Market bids up stock over the past week After last week's 34% share price gain to €22.80, the stock is trading at a trailing P/E ratio of 52x, up from the previous P/E ratio of 38.8x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 32%. Is New 90 Day High Low • Nov 10
New 90-day high: €16.60 The company is up 57% from its price of €10.60 on 11 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.93 per share. Valuation Update With 7 Day Price Move • Nov 02
Market bids up stock over the past week After last week's 21% share price gain to €16.00, the stock is trading at a trailing P/E ratio of 36.5x, up from the previous P/E ratio of 30.1x. This compares to an average P/E of 24x in the Chemicals industry in Germany. Total returns to shareholders over the past three years were flat. Valuation Update With 7 Day Price Move • Oct 21
Market bids up stock over the past week After last week's 15% share price gain to €13.50, the stock is trading at a trailing P/E ratio of 30.8x, up from the previous P/E ratio of 26.7x. This compares to an average P/E of 30x in the Chemicals industry in Germany. Total return to shareholders over the past three years is a loss of 20%. Is New 90 Day High Low • Oct 19
New 90-day high: €13.20 The company is up 17% from its price of €11.30 on 21 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.79 per share. Is New 90 Day High Low • Oct 02
New 90-day high: €12.40 The company is up 2.0% from its price of €12.10 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.73 per share.